Deep Track Capital Strengthens LB Pharma Position with $10M Pre-Funded Warrant Buy
LBRX has more than doubled off its 52-week low of $13.36 on elevated volume (3.1× avg).
Summary
Deep Track Biotechnology Master Fund, a 10% owner of LB Pharmaceuticals, bought $10 million in pre-funded warrants at $34.94 each, signaling strong institutional conviction on the heels of the company's recent $150 million private placement.
Key Events · Ownership and Investor Activity · LBRX
-
$10M Pre-Funded Warrant Purchase
Deep Track Biotechnology Master Fund acquired 286,205 pre-funded warrants at $34.94 per warrant, totaling $9,999,974. The warrants are exercisable immediately at $0.0001 per share and do not expire.
-
Participation in $150M Private Placement
The purchase occurred on July 30, 2026, one day after LB Pharmaceuticals announced a $150 million private placement, indicating Deep Track's participation in that offering.
-
Institutional Conviction Signal
The $10 million commitment from a 10% owner reinforces confidence in the company's lead candidate LB-102, currently in a pivotal Phase 3 trial for schizophrenia that is enrolling ahead of schedule.
-
Post-Transaction Holdings
Following the transaction, Deep Track Biotechnology Master Fund holds 664,649 pre-funded warrants, with an additional 93,925 warrants held by an affiliated fund, Deep Track Special Opportunities Fund, LP.
Analysis · LBRX · Life Sciences
A 10% owner, Deep Track Biotechnology Master Fund, has acquired 286,205 pre-funded warrants at $34.94 each, totaling $10 million. These warrants are immediately exercisable at $0.0001 per share and carry no expiration, granting the fund the right to obtain an equivalent number of common shares. The purchase comes just one day after LB Pharmaceuticals announced a $150 million private placement, suggesting the fund participated in that offering. This significant capital commitment from a major institutional investor reinforces confidence in the company's clinical pipeline, particularly the pivotal Phase 3 NOVA-2 trial for LB-102 in schizophrenia, which is enrolling ahead of schedule.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 29.5% of the 1699 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LBRX was trading at $42.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $13.36 to $44.33. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.